<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">REPAGLINIDE <img border="0" src="../images/pr.gif"/></span><br/>(rep-a-gli'nide)<br/><span class="topboxtradename">Prandin, </span><span class="topboxtradename">GlucoNorm <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">hormones &amp; synthetic substitutes</span>; <span class="classification">antidiabetic agent</span>; <span class="classification">meglitinide</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.5 mg, 1 mg, 2 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Oral hypoglycemic agent that lowers blood glucose levels by stimulating release of insulin from the pancreatic islets.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Significantly reduces postprandial blood glucose in type 2 diabetes [preprandial blood glucose between 80 and 120 mg/dL and
         HbA<sub>1c</sub> (glycosylated Hgb 
      </p><h1><a name="uses">Uses</a></h1>
<p>Adjunct to diet and exercise in type 2 diabetes. May also be used in combination with metformin.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to repaglinide; insulin-dependent diabetes, diabetic ketoacidosis, hypoglycemia; severe renal dysfunction;
         pregnancy (category C), lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypoglycemia; loss of glycemic control due to secondary failure; hepatic impairment; older adults, surgery, fever, systemic
         infection, trauma. No studies have been done in children.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Type 2 Diabetes</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span>  Initial dose: 0.5 mg 1530 min a.c.; initial dose for patients previously using glucose-lowering agents: 12 mg
               1530 min a.c. (2 4 doses/d depending on meal pattern; max: 16 mg/d); dosage range: 0.54 mg 1530 min a.c.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give within 30 min of beginning a meal.</li>
<li>Store at 15°30° C (59°86° F) in a tightly closed container and protect from moisture.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Arthralgia, back pain, paresthesia, allergy. <span class="typehead">CNS:</span> Headache. <span class="typehead">CV:</span> Chest pain, angina. <span class="typehead">GI:</span> Nausea, diarrhea, constipation, vomiting, dyspepsia. <span class="typehead"> Respiratory:</span> URI, sinusitis, rhinitis, bronchitis. <span class="typehead">Metabolic:</span> <span class="speceff-common">Hypoglycemia.</span>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Erythromycin,</b> <b>ketoconazole</b> may inhibit metabolism and potentiate hypoglycemia; <span class="classification">barbiturates</span>, <b>carbamazepine,</b> <b>rifabutin,</b> <b>rifampin,</b> <b>rifapentine,</b> <b>pioglitazone</b> may induce metabolism and cause hyperglycemia; <b>gemfibrozil</b> may increase risk of hypoglycemia and duration of action. <span class="typehead">Herbal:</span> <b>Ginseng,</b> <b>garlic</b> may increase hypoglycemic effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract, 56% bioavailability. <span class="typehead">Peak:</span> 1 h. <span class="typehead">Distribution:</span> 98% protein bound. <span class="typehead">Metabolism:</span> Metabolized in liver by cytochrome P450 3A4. <span class="typehead">Elimination:</span> 90% excreted in feces. <span class="typehead">Half-Life:</span> 1 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Frequent FBS and postprandial blood glucose monitoring and HbA<sub>1c</sub> q3mo to determine effective dose.
         </li>
<li>Monitor carefully for S&amp;S of hypoglycemia especially during the 1-wk period following transfer from a longer-acting sulfonylurea
            such as chlorpropamide.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Take only with meals to lessen the chance of hypoglycemia. If a meal is skipped, skip a dose; if a meal is added, add a dose.</li>
<li>Start repaglinide the morning after the other agent is stopped when changing from another oral hypoglycemia drug.</li>
<li>Be alert for S&amp;S of hyperglycemia or hypoglycemia (see Appendix F); report poor blood glucose control to physician.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>